# Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes

> **NCT05457933** · PHASE4 · COMPLETED · sponsor: **Medanta, The Medicity, India** · enrollment: 250 (actual)

## Conditions studied

- Type2diabetes
- Coronary Artery Disease

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Glargine

## Key facts

- **NCT ID:** NCT05457933
- **Lead sponsor:** Medanta, The Medicity, India
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-29
- **Primary completion:** 2023-01-14
- **Final completion:** 2023-01-14
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2023-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05457933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05457933, "Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05457933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*